Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-fluciclovine PET for Brain Metastases vs Radiation Necrosis
NCT03930173Phase 1Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jul 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluciclovine f 18 in brain metastases, sponsored by Case Comprehensive Cancer Center. Primary endpoint: Accuracy of 18F-fluciclovine PET as measured by area under the ROC curve up to 1 year. Started Jul 2019; status: completed.
02
Drugs
fluciclovine f 18
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT03930173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03930173.